Service
@{item.Title}
News
Cosmetic Supervision and Sampling Inspection Data and Information Sharing-October 2025
This article provides a consolidated overview of the relevant regulatory notices, supplemented by recent developments in regulatory enforcement activities-such as unannounced inspections and sampling inspections-conducted by the National Medical Products Administration (NMPA) and selected provincial and municipal authorities. The aim is to assist enterprises in staying informed of evolving regulatory trends and to reinforce awareness of quality management and compliance requirements.
11-17
Is Your Scalp Healthy? – Scalp Health Evaluation Methods (Part II)
In our last article, Is Your Scalp Healthy? – Scalp Health Evaluation Methods (Part I), we have introduced the evaluation methods for dandruff, sebum levels, and itchiness.
In this article, we will continue with the evaluation methods for erythema/papules/pustules and the overall hair status.
11-13
Global Cosmetics Regulatory Updates- Vol.31 (September 2025)
This article compiles and summarizes the latest developments in cosmetics regulations in China and globally as of September 2025, covering industry news, newly issued regulations, relevant policy adjustments, and regulatory requirements. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.
10-11
How is the Toxicity of New Cosmetic Ingredients "Calculated"? - A Technical Analysis of Computational Models for Predicting New Ingredient Toxicity
Since the concept of New Approach Methodologies (NAMs) was introduced, various methods including in vitro approaches, Threshold of Toxicological Concern (TTC), and computational models have gained favor among toxicological assessment experts. With the increasing capabilities of computational models, key toxicological endpoints such as acute toxicity, skin/eye irritation, sensitization, chronic toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and toxicokinetics can now be predicted using QSAR models.
10-09
Why choose CIRS Biotech?
Global Resources
With HQs in China, CIRS Group has branch companies in USA, UK, France, Korea, Japan, Ireland, that can provide cutting edge technical information and support to our clients
Rich Experience
CIRS Group has 17 years accumulation on testing and compliance service technical abilities. CIRS Group has served more than 20,000 clients, including 60+ world top 500 companies
One-Stop-Service Capability
Service range includes cosmetic ingredient development, physical/chemical tests, in-vivo toxicological tests, toxicology risk assessment, in-vitro toxicological study, clinical efficacy study, in-vitro efficacy study, raw material registration, product registration and etc.
Experts Team
Technical team built with experts from personal care industry, College Professor, Risk Assessment Expert, Toxicological Expert, Regulatory Compliance Expert
Professional Equipment and Technique
Capability includes the professional instruments and techniques for in-vitro efficacy study, in-vitro safety study, clinical efficacy study, in-vitro study method development, ingredient development and improvement
Why choose CIRS Biotech?
01
Global Resources
With HQs in China, CIRS Group has branch companies in USA, UK, France, Korea, Japan, Ireland, that can provide cutting edge technical information and support to our clients
02
Rich Experience
CIRS Group has 17 years accumulation on testing and compliance service technical abilities. CIRS Group has served more than 20,000 clients, including 60+ world top 500 companies
03
Experts Team
Technical team built with experts from personal care industry, College Professor, Risk Assessment Expert, Toxicological Expert, Regulatory Compliance Expert
04
One-Stop-Service Capability
Service range includes cosmetic ingredient development, physical/chemical tests, in-vivo toxicological tests, toxicology risk assessment, in-vitro toxicological study, clinical efficacy study, in-vitro efficacy study, raw material registration, product registration and etc.
05
Professional Equipment and Technique
Capability includes the professional instruments and techniques for in-vitro efficacy study, in-vitro safety study, clinical efficacy study, in-vitro study method development, ingredient development and improvement